# S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/s7b-nonclinical-evaluation-of-the-potential-for-delayed-ventricular-repolarization-qt-interval-prolongation-by-human-pharmaceuticals/816481d6-42de-481e-8388-3a53fc8330cc

> FDA guidance document: S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. Issue date: October 20, 2005. Get complete insights and analysis.

---

## Details

- Title: S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2005-10-20
- Last Changed: 2025-02-03
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2004-D-0366">FDA-2004-D-0366</a>

## Related Documents

- [E2E Pharmacovigilance Planning](https://www.globalkeysolutions.net/guidances/guidance-document/e2e-pharmacovigilance-planning/89ea2b55-7e7d-4a99-9e7f-9aac73abf09b)
- [E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs](https://www.globalkeysolutions.net/guidances/guidance-document/e14-clinical-evaluation-of-qtqtc-interval-prolongation-and-proarrhythmic-potential-for-non-antiarrhythmic-drugs/c83f1589-7be1-4064-93e8-eedcbfd73f95)
- [S8 Immunotoxicity Studies for Human Pharmaceuticals](https://www.globalkeysolutions.net/guidances/guidance-document/s8-immunotoxicity-studies-for-human-pharmaceuticals/216b9605-e0e0-4dd4-a10b-a51326a268f5)